All conditions

Migraine

Plain English clinical trial information, updated daily from ClinicalTrials.gov and public government registries. Not medical advice.

1586
Trials on record
173
Recruiting now
3
Australian sites
21
Phase 3 trials
10
PBS medicines
How these figures are counted
  • Trials on record is every trial tagged to this condition at any stage, except those withdrawn before starting or terminated early. Most are completed rather than ongoing, so this is a measure of research history, not of current activity. It is also smaller than the sitewide "trials tracked" figure, which does include withdrawn and terminated trials.
  • Recruiting now counts only trials whose registry status is "Recruiting". Trials listed as not yet recruiting or enrolling by invitation are excluded, so this understates how many may open to new participants soon.
  • Australian sites counts trials counted under "Recruiting now" that list at least one Australian site. A site being listed does not mean it is currently enrolling, and Australian trials registered only on ANZCTR are not counted yet, so this understates local availability.
  • Phase 3 trials counts trials counted under "Recruiting now" that are at Phase 3.

Find recruiting trials for Migraine →

Get alerts when Migraine trials change ↗

Voxsanity currently covers 103 conditions. We are expanding coverage regularly.

Understanding Migraine

Migraine is a neurological condition that causes recurring headaches, usually felt as a throbbing or pulsing pain on one side of the head. The headaches can last anywhere from a few hours to several days and are often severe enough to make everyday activities difficult. Many people with migraine also experience other symptoms such as nausea, vomiting, and sensitivity to light, sound, or smell. Some people experience an "aura" before or during a headache — this can include visual disturbances like flashing lights or blind spots, tingling sensations, or difficulty speaking. Migraine is considered a complex brain condition, and researchers continue to learn more about the mechanisms behind it.

Migraine is very common in Australia, affecting around 4.9 million Australians. It can affect people of any age, including children, but is most common in adults between their 20s and 50s. Women are affected more often than men, largely due to hormonal factors. For many people, migraine attacks are triggered by things like stress, certain foods or drinks, changes in sleep patterns, bright lights, or hormonal changes — though triggers vary greatly from person to person.

Treatment for migraine generally falls into two broad categories: managing symptoms during an attack, and taking steps to reduce how often attacks happen. Doctors may discuss a range of options depending on how frequent and severe a person's migraines are, their overall health, and how migraine affects their daily life. There are both medication-based and non-medication approaches available. A GP or specialist, such as a neurologist, is the best person to talk through which options might suit an individual's situation.

This overview is an AI generated summary written from public medical sources and checked on a sample basis. It is general information, not medical advice or a diagnosis. Always speak with your doctor about your situation. How we use AI

Can you access treatment for Migraine in Australia right now? Here's what's publicly known.

Information on this site does not constitute medical advice. Data is sourced from publicly available government registries. Always consult your doctor before making any health decisions. Trial status should be verified directly with the trial site.

Updated regularly from public government registries

PBS-subsidised medicines for Migraine

10 medicines listed on the PBS for Migraine. Filter by authority type, or open the full table below.

What the authority types mean Unrestricted: no clinical criteria; a doctor can prescribe it on the PBS for any appropriate use. Restricted benefit: subsidised only for the specific conditions or uses set out by the PBS. Streamlined authority: restricted, but the doctor does not need prior approval; they record a streamlined authority code confirming you meet the criteria. Authority required: restricted, and the doctor must get prior approval from Services Australia (by phone or online) before it is subsidised. Source: Pharmaceutical Benefits Scheme (pbs.gov.au).
Full PBS medicines table 10 listed

These medicines are listed on the Pharmaceutical Benefits Scheme (PBS) for the specific indications shown. A listing does not mean a medicine is right for you; your doctor decides what is appropriate. Prices shown are the PBS-determined dispensed price. Most patients pay only the standard co-payment, up to AU$25.00 per script (general) or AU$7.70 (concession or Safety Net) in 2026, with the Australian Government subsidising the rest.

Medicine Brand(s) Listed for
Eletriptan Relpax Migraine attack AU$12.68 Restricted benefit
Naratriptan Naramig Migraine attack AU$4.98 Authority required
Rizatriptan RIXALT, Rizatriptan Wafers-10mg Migraine attack AU$4 Restricted benefit
Sumatriptan Imigran FDT, Pharmacor Sumatriptan 50, APO-Sumatriptan Migraine attack AU$2.9 Restricted benefit
Zolmitriptan Zomig Migraine attack AU$5.52 Restricted benefit
Botulinum toxin type A Botox migraine AU$262.5 Streamlined authority
Eptinezumab Vyepti migraine AU$1317.59 Streamlined authority
Topiramate APO-Topiramate migraine AU$4 Streamlined authority
Fremanezumab Ajovy Treatment-resistant migraine AU$488.89 Streamlined authority
Galcanezumab Emgality Treatment-resistant migraine AU$463 Streamlined authority

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.

Research pipeline

Where trials for Migraine currently sit in the development pipeline. The funnel shape shows how few drugs reach later phases in general; the counts are this condition's actual trial numbers.

Phase success rates are industry-wide historical averages, not predictions for specific trials. Learn how trials work →

Most active research sponsors

Organisations with the most recruiting trials for Migraine.

View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile
View sponsor profile

Where trials are running

Clinical trial sites for Migraine by country. Australia is highlighted.

Showing the top 10 of 46 countries with trial sites.

Clinical trials for Migraine

Showing 177 of 177 trials

The plain English eligibility text on each trial below is an AI generated summary of the official criteria, checked on a sample basis. How we use AI

🇦🇺 NCT01516892 · Allergan Phase 4 · 3 countries Completed
Completed Phase 4 Est. completion 1 November 2015
🇦🇺 AU🇰🇷 KR🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with chronic migraine, meaning you get headaches on 15 or more days per month, with each headache lasting at least 4 hours Who may not be able to join: - You have been diagnosed with myasthenia gravis, Eaton-Lambert Syndrome, or amyotrophic lateral sclero...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT03971071 · Amgen Phase 4 · 12 countries Completed
Completed Phase 4 Est. completion 1 December 2022
🇦🇺 AU🇦🇹 AT🇨🇿 CZ🇫🇮 FI🇫🇷 FR🇭🇺 HU🇮🇹 IT🇵🇱 PL +4 more

Who might be able to join this trial: - You are 18 years of age or older - You have been diagnosed with migraine (with or without aura) for at least 12 months before joining - You have had chronic migraine for at least 6 months before joining - You are currently diagnosed with medication overuse headache (a condition w...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT05452239 · H. Lundbeck A/S Phase 4 · 11 countries Completed
Completed Phase 4 Est. completion 22 October 2024
🇦🇺 AU🇩🇰 DK🇫🇷 FR🇬🇪 GE🇩🇪 DE🇮🇹 IT🇳🇱 NL🇳🇴 NO +3 more

**Who might be able to join this trial:** - You have been diagnosed with migraine or medication overuse headache, confirmed by a doctor using established guidelines at a screening visit. - You have had at least 8 migraine days per month, every month, for the past 3 months. - You have had at least 15 headache days per m...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
🇦🇺 NCT05700318 · ShiraTronics Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2025
🇦🇺 AU

**Who might be able to join this trial:** - People who are 22 years of age or older. - People who have had a history of migraines for at least 12 months. - People who experience between 15 and 26 headache days per month, with at least 8 of those days involving migraine-type headaches. - People who have not responded we...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06450444 · Salvia BioElectronics Not Applicable · 3 countries Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇦🇺 AU🇧🇪 BE🇳🇱 NL

Who might be able to join this trial: - People who have been diagnosed with migraine (with or without aura, as defined by international headache classification standards) and have had chronic or high-frequency episodic migraine for at least one year before screening - People for whom 3 or more preventive migraine medic...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
🇦🇺 NCT06625060 · Ipsen Phase 2 · 14 countries Recruiting
Recruiting Phase 2 Est. completion 31 October 2027
🇦🇺 AU🇧🇷 BR🇨🇦 CA🇨🇿 CZ🇫🇷 FR🇬🇪 GE🇩🇪 DE🇯🇵 JP +6 more

**Who might be able to join this trial:** - People who are able to give written consent and agree to follow the study's requirements - People aged 18 to 80 years old at the time of signing the consent form - People who have been diagnosed with either episodic migraine (EM) or chronic migraine (CM), according to recogn...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03844412 · Duke University Phase 2 · 1 country Completed
Completed Phase 2 Est. completion 13 March 2024
🇺🇸 US

**Who might be able to join this trial:** - You are a woman between 18 and 50 years old - You are able to read and understand English - You are willing to give your formal agreement to participate in the study - You have had pain at the entrance to the vagina during sex and/or pain when inserting a tampon or being touc...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT03231241 · Stanford University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 August 2026
🇺🇸 US

**Who might be able to join this trial:** - You must be willing to sign a consent form agreeing to take part in the study. - You must be able to complete online questionnaires in English, either on your own or with some help. - You must be willing to follow the study's instructions throughout the trial. - You must be a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03404336 · University of Florence Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are willing to take part and have signed a consent form agreeing to participate - You are between 18 and 65 years old - Italian is your first language - You have been diagnosed with chronic migraine, meaning you experience headaches on 15 or more days per month with sympt...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03694626 · Randy Kardon Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇺🇸 US

Who might be able to join this trial: **Healthy Control Group** - People aged 18 to 80 who are generally healthy - People who have had a normal eye examination within the past year **TBI Patients Without Light Sensitivity or Headache** - People aged 18 to 80 who have had a traumatic brain injury (TBI — an injury to t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT03972124 · University of Calgary Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2028
🇨🇦 CA

**Who might be able to join this trial:** - You are willing and able to sign a consent form agreeing to take part in the study. - You are male or female and are 25 years of age or older. - You have been diagnosed with migraines for at least 12 months, based on standard medical guidelines for headache disorders. - You...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04063540 · Centre Hospitalier Universitaire de Nice Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2027
🇫🇷 FR

**Who might be able to join this trial:** - You have been diagnosed with migraine with aura (a type of migraine that includes warning symptoms like visual disturbances before the headache) - You have had at least one migraine with aura per month for the 3 months before joining the trial - You have not been taking any r...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04151472 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People who have been clinically diagnosed with episodic migraine (migraine that comes and goes, rather than being constant). - People between 18 and 65 years of age whose migraine diagnosis meets the International Headache Society criteria, with a migraine history of at leas...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04628429 · Medical University of Vienna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇦🇹 AT

**Who might be able to join this trial:** - You have been diagnosed with chronic migraine (frequent migraines occurring most days of the month) - You have been diagnosed with episodic migraine, either with or without warning symptoms (such as visual disturbances) before the headache - You have already tried 3 or more s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04649242 · Pfizer Phase 3 · 9 countries Recruiting
Recruiting Phase 3 Est. completion 9 January 2029
🇨🇦 CA🇨🇳 CN🇯🇵 JP🇲🇽 MX🇵🇱 PL🇪🇸 ES🇸🇪 SE🇬🇧 GB +1 more

**Who might be able to join this trial:** - You have had migraines (with or without aura) for more than 6 months before the screening appointment, confirmed by medical records and/or your own memory (or a parent's/guardian's memory). - You have had between 1 and 8 moderate or severe migraine attacks per month in the 2...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04686253 · China National Center for Cardiovascular Diseases Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2028
🇨🇳 CN

Who might be able to join this trial: - People aged 16 to 65 years who have no known vascular risk factors, such as high blood pressure, high cholesterol, diabetes, atrial fibrillation, smoking, or obesity - People who have a confirmed hole in the heart called a PFO (patent foramen ovale), with a significant amount of...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04715685 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2026
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with migraine (with or without aura) or chronic migraine that meets standard medical diagnostic guidelines. - Over a 28-day headache diary, you have between 4 and 28 headache days per month. - Your migraine-related disability score (called PedMIDAS) is abo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04743141 · Pfizer Phase 3 · 3 countries Recruiting
Recruiting Phase 3 Est. completion 31 July 2030
🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have had migraines (with or without aura) for at least 6 months before the screening appointment. - You have had between 1 and 8 moderate or severe migraine attacks per month in the 2 months before screening. - You had at least 1 migraine day that needed treatment during...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04748601 · Upsher-Smith Laboratories Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - Children who are female or male, aged 6 to 11 years old at the screening visit - Children who weigh at least 17.0 kg and less than 50.0 kg at the screening visit - Children who have had headaches consistent with a migraine diagnosis (with or without aura) for at least 6 mont...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04925414 · Centre Hospitalier Universitaire de Nice Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 April 2025
🇫🇷 FR

Who might be able to join this trial: - People aged 18 years or older - People who are covered by French public health insurance - People admitted to an emergency department with a headache that appears to be a migraine, based on recognised international diagnostic criteria - People who have given written agreement to...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT04930887 · Stanford University Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 June 2028
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 80 who have a clinic visit at Stanford Pain & ENT clinic and whose main complaint is a craniofacial (head and face) pain condition, such as migraine, cluster headache, trigeminal autonomic cephalgia, sphenopalatine ganglioneuralgia, or paroxysmal hemicrania...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT04939922 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 12 December 2050
🇨🇳 CN

**Who might be able to join this trial:** - You must be willing and able to sign a consent form agreeing to take part and allowing your health information to be used in the study. - You must be between 4 and 99 years old (male or female). - You must have been diagnosed with a headache condition that meets international...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT04965675 · H. Lundbeck A/S Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 5 September 2026
🇦🇷 AR🇨🇦 CA🇮🇹 IT🇲🇽 MX🇵🇱 PL🇵🇹 PT🇷🇸 RS🇪🇸 ES +3 more

Who might be able to join this trial: - People who have been diagnosed with migraine (with or without aura) according to standard medical guidelines, and have had chronic migraine for at least 6 months before the screening visit. - People who are willing and able to complete a daily headache diary on at least 23 out of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05046613 · Pfizer Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 November 2029
🇺🇸 US

**Who might be able to join this trial:** - People who are pregnant, have been diagnosed with migraine, and have taken at least one dose of rimegepant either during pregnancy or up to 3 days before becoming pregnant - People who are pregnant, have been diagnosed with migraine, and have never taken rimegepant before or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05125302 · AbbVie Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 May 2027
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People who have had a diagnosis of migraine (with or without aura) for at least 6 months, based on recognised international headache guidelines. - People whose migraines typically last between 3 and 72 hours when untreated or not fully treated, with at least 48 hours of bein...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05156398 · Pfizer Phase 3 · 7 countries Recruiting
Recruiting Phase 3 Est. completion 29 November 2031
🇨🇦 CA🇫🇷 FR🇮🇹 IT🇯🇵 JP🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - You have had migraines (with or without aura) for at least 6 months - You had 14 or fewer headache days per month in the 3 months before the screening visit - You had 6 or more migraine days during the observation period at the start of the study - You had 14 or fewer total...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05158894 · AbbVie Not Applicable · 2 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2036
🇨🇦 CA🇺🇸 US

**Who might be able to join this trial:** - You must be located in the United States or Canada. - You must currently be pregnant at the time of signing up. - You must have been diagnosed with migraines by your doctor or healthcare provider. - You must be willing to provide contact details for yourself, your doctor, an...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05164172 · H. Lundbeck A/S Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 30 April 2028
🇦🇷 AR🇨🇦 CA🇮🇹 IT🇲🇽 MX🇵🇱 PL🇵🇹 PT🇷🇸 RS🇪🇸 ES +3 more

Who might be able to join this trial: - People who have completed the Week 12 final visit of one of two specific earlier related studies (Study 19356A or Study 19357A) immediately before enrolling in this trial. Who may not be able to join: - People who experienced side effects or safety concerns during the earlier st...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05306899 · University Health Network, Toronto Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 February 2027
🇨🇦 CA

**Who might be able to join this trial:** - You are between 18 and 75 years old - You have been diagnosed with chronic daily headache, meaning you have headache episodes lasting 4 or more hours that occur on 15 or more days per month, for at least 3 months in a row - Your liver and kidney function tests are within norm...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05334927 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2031
🇨🇳 CN

**Who might be able to join this trial:** - You are 12 years old or older, of any gender - Your headaches first started before the age of 50 (or you were first diagnosed with chronic migraine before age 65) - You have been diagnosed with a primary headache condition (such as migraine, tension headache, or other primary...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05337033 · University of Manitoba Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2025
🇨🇦 CA

**Who might be able to join this trial:** - Adolescents who are between 14 and 17 years old at the time of screening - People diagnosed with Chronic Migraine, meaning headaches occurring on 15 or more days per month for more than 3 months, with at least 8 of those days having migraine features - People who have alread...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05342493 · Otsuka Pharmaceutical Co., Ltd. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2026
🇯🇵 JP

The eligibility criteria provided for this trial appear to be incomplete — the inclusion criteria section is blank, and only one exclusion criterion has been listed. Based on what is available, here is the plain English summary: "Who might be able to join this trial: - The inclusion criteria for this trial have not b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05415020 · Mayo Clinic Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇺🇸 US

Who might be able to join this trial: - People who have been experiencing chronic migraine for at least 1 year - People who are 18 years of age or older Who may not be able to join: - People who have other types of headache disorders, including headaches caused by another underlying condition - People who are under 18...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05418218 · Second Affiliated Hospital, School of Medicine, Zhejiang University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2082
🇨🇳 CN

**Who might be able to join this trial:** - You are willing and able to give written consent to participate in the study before any study procedures begin - You are male or female, aged 4 to 99 years old at your first visit - You have been diagnosed with a headache condition that meets recognised international headache...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05484349 · Second Affiliated Hospital, School of Medicine, Zhejiang University Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 25 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - Adults between 18 and 65 years of age (inclusive) - People who have been formally diagnosed with migraine (with or without aura) for at least 1 year, according to recognised international headache diagnostic standards - People whose first migraine occurred before the age of...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05524493 · University of Zurich Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇭 CH

**Who might be able to join this trial:** **For patients with a medical condition:** - You must be able to read and sign a consent form agreeing to take part - You must have been on stable preventive medication for at least 2 months before your MRI scan - You have been diagnosed with migraine (with or without aura, oc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05570149 · IRCCS San Raffaele Roma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - People aged between 18 and 75 years old - Both men and women are eligible - People who are willing to sign a consent form agreeing to take part in the trial - People who have had at least 8 days per month of severe, disabling migraine for the past 3 months (known as high frequenc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05582837 · University of California, Irvine Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 30 December 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have active or frequent Ménière's Disease - People aged between 25 and 85 years old, male or female - People who are willing and able to take the study medication as directed and attend all required appointments - People who can read and write in English in order t...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT05598723 · Naval Medical Center Camp Lejeune Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 24 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People aged between 18 and 89 years old - People who experience 15 or more headache days per month, where each headache lasts 4 hours or longer - People who are eligible for healthcare through the Department of Defense (DoD) or TriCare - People who have already tried two dif...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05654012 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 March 2028
🇺🇸 US

**Who might be able to join this trial:** *For healthy participants (no migraines):* - You are between 10 and 13 years old - You are male or female - You have not been diagnosed with migraines and do not have migraine symptoms - You either have a close family member (like a parent or sibling) diagnosed with migraine,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05669703 · National Institute of Mental Health (NIMH) Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2026
🇺🇸 US

**Who might be able to join this trial:** - You are willing to take part in all study activities and are available for the full length of the study - You are 8 years old or older - If you are the main participant (called a "proband"), at least one close family member (such as a parent, sibling, or child) must also agre...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05690737 · The Hong Kong Polytechnic University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
Hong Kong

**Who might be able to join this trial:** - You are a Chinese woman aged between 18 and 65 years old - You have been diagnosed with episodic migraine (fewer than 15 migraine attacks per month), with or without aura, based on recognised international headache guidelines - Your migraines first started before you were 45...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05711394 · AbbVie Phase 3 · 16 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2028
🇧🇪 BE🇨🇦 CA🇩🇰 DK🇫🇷 FR🇭🇺 HU🇮🇱 IL🇮🇹 IT🇯🇵 JP +8 more

Who might be able to join this trial: - Your child weighs at least 44 lbs (20 kg) and less than 298 lbs (135 kg). - Your child has had episodic migraines (with or without visual or sensory warning signs called "aura") for at least 6 months. - During the 28-day tracking period before the trial, your child had between 4...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05734625 · Mayo Clinic Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 February 2027
🇺🇸 US

**Who might be able to join this trial:** - People who experience episodic migraines at least 4 times a month but fewer than 15 times a month, with pain rated 5 out of 10 or higher - People who are willing to keep their migraine medications the same throughout the six months of the trial — not starting or stopping any...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05752396 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇺🇸 US

**Who might be able to join this trial:** **For all participants:** - You must have access to the internet through a laptop, tablet, or phone (for completing online surveys) - You must be able to speak and understand English - A parent or guardian must be willing to follow the study rules, complete assessments, and si...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05769348 · University of Michigan Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 65 years old (male or female) - People whose migraines first started before the age of 50 - People who currently have chronic migraine, meaning headaches on 15 or more days per month for more than six months, with at least 8 of those days having migraine fe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05889624 · Children's Hospital Medical Center, Cincinnati Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 July 2027
🇺🇸 US

**Who might be able to join this trial:** - People who have been diagnosed with migraine (with or without aura) according to standard headache disorder guidelines, or who have ongoing headaches that include migraine episodes — including those who may be overusing pain medications - People who have had 4 or more headac...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05897320 · H. Lundbeck A/S Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 6 July 2027
🇦🇷 AR🇨🇦 CA🇮🇹 IT🇲🇽 MX🇵🇱 PL🇵🇹 PT🇷🇸 RS🇪🇸 ES +3 more

**Who might be able to join this trial:** - People who have been diagnosed with migraine (with or without aura) for at least 6 months before the screening visit, based on recognised international headache diagnosis guidelines. - People who consistently fill in a daily headache diary on an electronic device for at leas...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT05903027 · University of Florence Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 June 2024
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with migraine without aura, migraine with aura, or chronic migraine, based on internationally recognised diagnostic guidelines (ICHD-III) - People who experience at least 3 migraine days per month - People who are able and willing to follow the stud...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05943457 · Sola Aoun Bahous, M.D. Ph.D. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇱🇧 LB

**Who might be able to join this trial:** - You are 18 years old or older - You have been diagnosed with episodic migraine (with or without aura) for more than 12 months, based on recognised international headache guidelines - You experienced migraines on 4 to 14 days per month in the 3 months before the screening visi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT05987592 · Wake Forest University Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You have been diagnosed with migraine (with or without aura) and have headaches on 4 to 20 days per month - You have had migraines for at least 1 year - You are at least 18 years old - You are able to attend 8 weekly online classes - You are willing to keep a headache diary b...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06016465 · Texas Tech University Health Sciences Center, El Paso Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 30 December 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with migraines that meet specific international medical guidelines (called ICHD-3 criteria) - After receiving a nerve block treatment, your headache pain dropped by at least 5 points on a pain scale, or your pain score afterwards was between 0 and 2 out of...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06077838 · NYU Langone Health Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2028
🇺🇸 US

**Who might be able to join this trial:** - People who speak English (the app used in this trial is currently only available in English) - People aged 16 or older - People whose headaches meet a recognised medical definition of migraine, based on information assessed during the study screening process - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06085144 · University of California, San Francisco Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2026
🇺🇸 US

Who might be able to join this trial: - People who are female and between 18 and 45 years of age - People who have an established diagnosis of migraine - People who had a straightforward delivery without lasting health complications for themselves - People whose baby did not stay in a neonatal intensive care unit (NICU...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06150781 · Amgen Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 October 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older at the time of signing the consent form - You are currently pregnant - The outcome of your pregnancy is not yet known (for example, it has not ended) - You have been officially diagnosed with migraines by a doctor **Who may not be able to joi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06203873 · Chinese Academy of Medical Sciences, Fuwai Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2026
🇨🇳 CN

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have been diagnosed with migraine according to standard medical guidelines (called ICHD-3) - You have had migraines for more than 1 year, and they seriously affect your everyday life - You have been diagnosed with a small hole in the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06219694 · Taichung Veterans General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 4 May 2022
🇹🇼 TW

Who might be able to join this trial: - People aged 21 or older who have chronic migraine that is being managed with medication, including preventive medications, acute (as-needed) medications, or both — as well as people who have declined preventive medication even after their neurologist recommended it. - People who...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06224959 · University Hospital, Clermont-Ferrand Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 27 March 2028
🇫🇷 FR

Who might be able to join this trial: - You are 18 years old or older - You have been diagnosed with osteoarthritis affecting your joints, your spine, or both - You are covered by a social security (health insurance) system - You are able to read and understand French Who may not be able to join: - You do not wish to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06229834 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have been diagnosed with migraine (with or without aura) that is not classified as "chronic migraine" by your doctor - You have had migraines for at least one year - You have had between 4 and 13 migraine days per month during an ini...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06248671 · St. Olavs Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇳🇴 NO

**Who might be able to join this trial:** - You are between 18 and 65 years old. - You are willing and able to sign a consent form agreeing to take part in the study. - You have been diagnosed with episodic migraine (with or without aura) according to recognised international guidelines. - You have had between 4 and 14...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06277063 · Nanfang Hospital, Southern Medical University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 August 2026
🇨🇳 CN

**Who might be able to join this trial:** - People diagnosed with migraine, cluster headache, or tension-type headache according to Chinese medical guidelines (2022 editions) - People aged 7 to 20 years old - People who have had headaches on between 3 and 15 days per month in the past - People who have been on a stabl...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06309251 · Danone Nutricia SpA Società Benefit Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2025
🇮🇹 IT

Who might be able to join this trial: - Children under 18 years old who have epilepsy that has not been controlled by at least two different seizure medications, and who are being treated with a ketogenic diet (a special high-fat, low-carbohydrate diet) - Children under 18 years old who have a genetic, metabolic, or ne...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06322407 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇨🇳 CN

**Who might be able to join this trial:** - People between 18 and 65 years old - People who have been diagnosed with chronic migraine based on internationally recognised diagnostic criteria - People who have either never tried preventive migraine treatments before, or who have tried up to three standard preventive trea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06398353 · Chang Gung Memorial Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇹🇼 TW

**Who might be able to join this trial:** - You are willing to sign a written consent form to take part in the study - You are male or female and are 18 years of age or older - You experience headaches (such as dizziness, heavy head feeling, head fullness, or migraines) more than twice a week, and your pain level is ra...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06401642 · Mayo Clinic Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with migraine (with or without aura) according to standard medical guidelines - You are at least 18 years old - You experience between 2 and 8 migraine attacks per month - You are already taking one of the following migraine prevention medications at a ste...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06409832 · University of Florence Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇮🇹 IT

**Who might be able to join this trial:** - You have been diagnosed with migraine (either with or without aura) based on recognised medical guidelines - You experience at least 4 days per month where you have a migraine - You are willing and able to follow the study's procedures and requirements - You have kept a heada...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06459635 · Fundación de Investigación Biomédica - Hospital Universitario de La Pr... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇪🇸 ES

**Who might be able to join this trial:** - You are between 15 and 69 years old. - You have been diagnosed with migraine by a neurologist who specialises in headaches, using established international guidelines. - You have had migraines for at least 1 year. - Your neurological examination (a check of your nervous syste...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06459648 · Fundación de Investigación Biomédica - Hospital Universitario de La Pr... Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
🇪🇸 ES

Who might be able to join this trial: - People aged between 18 and 65 years. - People of Caucasian ethnicity. - People who have been diagnosed by a headache specialist neurologist with either high-frequency episodic migraine (more than 8 migraine days per month) or chronic migraine, based on recognised international he...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06473597 · Antonios Likourezos Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 31 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 65 years old and were seen in the emergency department - You came in with a headache that started recently (acute headache) - Your pain level is at least 5 out of 10 on a pain scale - You are fully awake, alert, and know who you are, where you are, and...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06485336 · St. Olavs Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 31 December 2028
🇳🇴 NO

**Who might be able to join this trial:** - People aged between 18 and 64 years - People who have given written consent to participate - People diagnosed with chronic migraine according to established international diagnostic guidelines (ICHD-3) - People who have had at least 15 headache days per month, including at l...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06485726 · Kafrelsheikh University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2024
🇪🇬 EG

**Who might be able to join this trial:** - You are between 18 and 75 years old and have been diagnosed with migraine (with no previous treatment for it) according to standard international guidelines. **Who may not be able to join:** - You have a major neurological condition such as epilepsy, stroke, multiple scleros...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06503328 · IRCCS National Neurological Institute "C. Mondino" Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2024
🇮🇹 IT

Who might be able to join this trial: **As a Healthy Control participant:** - Adults aged between 18 and 65 years who do not have a headache disorder (occasional tension-type headache is acceptable) **As an Episodic Cluster Headache participant:** - Adults aged between 18 and 65 years of any gender who have been diag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06503848 · Hospital Universitari Vall d'Hebron Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2024
🇪🇸 ES

Who might be able to join this trial: - People who have been diagnosed with migraine (with or without aura) according to recognised international headache diagnostic standards - People who experience fewer than 8 migraine days per month - People who are able to read, write, and understand instructions - People who have...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06504537 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2024
🇵🇰 PK

**Who might be able to join this trial:** - People of any gender are eligible - People between 18 and 65 years old - People who have been diagnosed with migraine without aura (migraine without visual disturbances or other warning signs before the headache) - People whose migraines include nausea or vomiting, along with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06507150 · Ente Ospedaliero Cantonale, Bellinzona Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2027
🇨🇭 CH

Who might be able to join this trial: - People who are between 18 and 65 years old at the time of signing the consent form - People who have been newly diagnosed with migraine, confirmed through their medical records - People who are able to understand and sign a consent form agreeing to take part - People who have acc...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06509503 · Kafrelsheikh University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 May 2025
🇪🇬 EG

Who might be able to join this trial: - Women aged 18 to 55 years who have been diagnosed with migraines, based on a specific set of international headache guidelines - Women who are using either a combined oral contraceptive pill or a non-hormonal (mechanical) form of contraception Who may not be able to join: - Peop...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06549270 · IRCCS National Neurological Institute "C. Mondino" Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇮🇹 IT

Who might be able to join this trial: - You are a man or woman between 18 and 75 years old - You have been diagnosed with episodic migraine or chronic migraine (based on standard international diagnostic guidelines) - If you have episodic migraine, you have had between 8 and 14 migraine days per month over the past 3 m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06554886 · St. Olavs Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 January 2026
🇳🇴 NO

**Who might be able to join this trial:** - People who are 18 years of age or older at the time of signing the consent form - People who have been diagnosed with chronic migraine (with or without aura) according to international headache classification standards, confirmed by a neurologist - People who have had at lea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06558578 · Sohag University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 July 2025
🇪🇬 EG

Who might be able to join this trial: - Children between 6 and 16 years old (inclusive) - Both boys and girls are eligible - Children who have been diagnosed with migraines Who may not be able to join: - Children younger than 6 years old or older than 16 years old - Children who have been diagnosed with epilepsy (a co...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06562400 · IRCCS National Neurological Institute "C. Mondino" Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2024
🇮🇹 IT

Who might be able to join this trial: - Men and women between 18 and 75 years old - People who have been diagnosed with episodic migraine or chronic migraine based on recognised international diagnostic guidelines - People with episodic migraine who have had between 8 and 14 migraine days per month over the past 3 mont...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06562413 · IRCCS National Neurological Institute "C. Mondino" Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 February 2026
🇮🇹 IT

Who might be able to join this trial: - You are a man or woman between 18 and 75 years old - You have been diagnosed with episodic migraine or chronic migraine based on recognized international diagnostic guidelines - If you have episodic migraine, you have been experiencing between 8 and 14 migraine days per month ove...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06584409 · Taichung Veterans General Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2025
🇹🇼 TW

Who might be able to join this trial: - People who have been diagnosed with migraine, confirmed using a standard international headache classification system called ICHD-3. Who may not be able to join: - People who are under 18 years old. - People who are currently pregnant. Important: Always verify eligibility with...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06602479 · AbbVie Phase 2 · 8 countries Recruiting
Recruiting Phase 2 Est. completion 18 December 2026
🇨🇿 CZ🇩🇰 DK🇩🇪 DE🇭🇺 HU🇮🇹 IT🇵🇱 PL🇪🇸 ES🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 70 years old. - People who weigh at least 40 kg and have a body mass index (BMI) of 18.0 or above. - People who have had migraines (with or without aura) for at least 12 months before screening, where migraines first started at age 50 or younger. - People w...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06603558 · AbbVie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2029
🇰🇷 KR

Who might be able to join this trial: - People who have migraines and whose condition is suitable for treatment with atogepant, based on the most current approved guidelines in their country. - People for whom a doctor has prescribed atogepant in line with the approved local guidelines. Who may not be able to join: -...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06616194 · Pfizer Phase 3 · 12 countries Recruiting
Recruiting Phase 3 Est. completion 8 October 2026
🇨🇦 CA🇨🇳 CN🇨🇿 CZ🇫🇮 FI🇭🇺 HU🇮🇳 IN🇮🇹 IT🇯🇵 JP +4 more

Who might be able to join this trial: - People who have had migraines (with or without aura) for at least 6 months. - People who experience 15 or more headache days per month. - People who experience 8 or more migraine days per month. - People whose migraines typically last between 4 and 72 hours when left untreated....

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06617832 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇩🇰 DK

Who might be able to join this trial: - Adults between 18 and 65 years old - People who have had a diagnosis of migraine (with or without aura) for at least 1 year, based on established international headache diagnostic guidelines - People with episodic migraine, meaning between 1 and fewer than 15 headache days per mo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06623188 · Hôpital Européen Marseille Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 November 2027
🇫🇷 FR

Who might be able to join this trial: - You are between 18 and 60 years old - You have had moderate to severe migraines for at least one year - Your migraines started before you were 50 years old and have been officially diagnosed using recognised international headache guidelines - At least 2 different migraine preven...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06628921 · University of Florence Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2026
🇮🇹 IT

**Who might be able to join this trial:** - People who have been diagnosed with migraine without aura, migraine with aura, or chronic migraine, as defined by the standard international headache diagnostic guidelines (ICHD-III). - People who experience at least 8 days of migraine per month. - People who are willing and...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06641466 · Pfizer Phase 3 · 15 countries Recruiting
Recruiting Phase 3 Est. completion 29 November 2026
🇦🇷 AR🇨🇦 CA🇨🇳 CN🇩🇰 DK🇩🇪 DE🇮🇳 IN🇮🇹 IT🇯🇵 JP +7 more

**Who might be able to join this trial:** - You have regular menstrual cycles that are between 24 and 34 days long - You have been diagnosed with migraine (with or without aura) for at least 1 year, following standard medical guidelines - You have had migraines linked to your menstrual cycle for at least 3 months - In...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06652724 · University of Roma La Sapienza Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 September 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are at least 18 years old - You have had at least 5 years of formal education - You have been diagnosed with fibromyalgia (FM) according to specific medical guidelines (Wolfe, 2016), if joining the fibromyalgia group - You have been diagnosed with chronic migraine (CM) ac...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06659120 · Insel Gruppe AG, University Hospital Bern Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇭 CH

**Who might be able to join this trial:** - Women who have not yet reached menopause and are 18 years of age or older - Women who have a regular menstrual cycle that is between 21 and 32 days long - People who have been diagnosed with chronic or episodic migraine - Women who have been experiencing migraine with or wit...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06662461 · Ain Shams University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2024
🇪🇬 EG

Who might be able to join this trial: - You have been diagnosed with long-lasting migraines that have not responded well to treatment, and you have either tried 2 or more migraine medications for at least 3 months without success, or you were unable to tolerate those medications. Who may not be able to join: - You hav...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06670053 · University of Colorado, Denver Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇺🇸 US

Who might be able to join this trial: - People who identify as transmasculine or gender diverse - People who were assigned female at birth - People who are between 12 and 20 years old at the time of joining the trial - People who are planning to start testosterone treatment within the next 6 months - People who are tak...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06674772 · Hospital Universitari Vall d'Hebron Research Institute Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2025
🇪🇸 ES

**Who might be able to join this trial:** - People who have been diagnosed with migraine according to standard medical diagnostic guidelines (ICHD-3 criteria) - Healthy volunteers (without headaches and without any close family members who have headaches) who are matched to a migraine patient by age and sex **Who may...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06684249 · Zagazig University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 May 2025
🇪🇬 EG

**Who might be able to join this trial:** - Adults between 18 and 65 years old. - People who have been diagnosed with chronic migraine, meaning they have headaches on 15 or more days per month for more than three months, with at least 8 of those days being migraine days. - People who are able to understand and agree to...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06690060 · Beth Israel Deaconess Medical Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2027
🇺🇸 US

Who might be able to join this trial: - You are 18 years of age or older - You have previously been diagnosed with migraine headaches by a doctor - Your migraines have a moderate or greater impact on your daily life, based on a standard headache questionnaire (confirm with trial site) - You experience migraine headache...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06716489 · University of Sao Paulo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 November 2028
🇧🇷 BR

**Who might be able to join this trial:** - You are a woman between 18 and 48 years old - You have been diagnosed with migraine by a specialist neurologist (a headache expert), using recognised international guidelines - You get headaches between 3 and 8 days per month **Who may not be able to join:** - You have anoth...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06735768 · Brightmind.AI Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2025
🇦🇹 AT

**Who might be able to join this trial:** - People aged 18 to 65 years old - People diagnosed with migraine without aura, migraine with aura, or chronic migraine, based on the standard international headache diagnostic guidelines (ICHD-3) - People whose migraines first started before the age of 50 - People who had at...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06735833 · Cerenovus, Part of DePuy Synthes Products, Inc. Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 25 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 65 years old at the time of signing up for the study - Your chronic migraine condition started at age 64 or younger - You were first diagnosed with migraines before the age of 50 - You have been diagnosed with migraines that have not responded well to s...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06745648 · Hospital Municipal Pedro T. Orellana Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2025
🇦🇷 AR

Who might be able to join this trial: - You must be at least 16 years old. - You must have been diagnosed with migraine, tension-type headache, or a mix of both types of headache. - Your current headache must have started within the last 24 hours. Who may not be able to join: - You cannot take part if there is any med...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06785129 · Washington University School of Medicine Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2028
🇺🇸 US

Who might be able to join this trial: - You have been diagnosed with endometriosis, migraines, or both - OR you are a healthy volunteer with no history of long-term (chronic) pain - You are between 12 and 45 years old - You were assigned female sex at birth Who may not be able to join: - You are currently pregnant or...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06788977 · Cefaly Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

**Who might be able to join this trial:** - People who are willing and able to give simple consent to take part in a registry. - People who have access to email or text messages through a smartphone or computer with internet. - People who are between 18 and 44 years old at the time of joining. - People who are pregnant...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06795867 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇺🇸 US

Who might be able to join this trial: - You are willing and able to take part in the consent process - You are willing to participate in the study, even if you are assigned to a group you didn't expect - You are available for the full length of the study - You have been diagnosed with chronic migraine and are being see...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06796725 · Ruijin Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 June 2026
🇨🇳 CN

**Who might be able to join this trial:** - People who have headaches on at least 15 days per month, and this pattern has been ongoing for at least 3 months, where those headaches have features of tension-type headaches or migraines - People who have had at least 5 headache episodes that meet the recognised medical cr...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06808230 · Brigham and Women's Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇺🇸 US

**Who might be able to join this trial:** - You are a man or woman aged 18 or older - A doctor has told you that you have migraine (with or without aura), and it is not classified as chronic migraine - You have been having migraines for at least one year - You had between 4 and 14 migraine attacks in the 30 days before...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06810505 · AbbVie Phase 3 · 11 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2031
🇨🇦 CA🇩🇰 DK🇭🇺 HU🇮🇹 IT🇯🇵 JP🇳🇱 NL🇵🇱 PL🇵🇹 PT +3 more

**Who might be able to join this trial:** - You have been diagnosed with chronic migraine (with or without aura) for at least 6 months before your first visit to the trial site. - During the 28-day screening period before joining, you filled in a daily digital diary on at least 20 out of 28 days. - During that same 28-...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06848166 · Vedanta University Clinic Early Phase 1 · 1 country Recruiting
Recruiting Early Phase 1 Est. completion 1 October 2026
Kyrgyzstan

**Who might be able to join this trial:** - The person has read, understood, signed, and dated the consent and information forms for the study. - The person is between 35 and 59 years old at the time of signing the consent form. - The person has been diagnosed with chronic migraine (according to specific Russian and i...

Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.
NCT06882122 · IRCCS National Neurological Institute "C. Mondino" Foundation Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - You are between 18 and 70 years old - You have been diagnosed with episodic migraine (using standard medical guidelines known as ICHD-3) - You have had between 8 and 14 migraine days per month over the past 3 months - You have never previously been treated with CGRP-targeted...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06893874 · Norwegian University of Science and Technology Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇳🇴 NO

**Who might be able to join this trial:** - You are 18 years old or older when you enter the trial - You have been diagnosed with episodic or chronic migraine, with or without aura, based on standard medical guidelines (confirm with trial site) - Your migraines first started before you were 50 years old - You have had...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06904287 · Wake Forest University Health Sciences Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 1 June 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years of age or older - You are able to understand and agree to take part in the study (give informed consent) - You are able to speak and communicate in English - You have been previously diagnosed with migraine and currently have a headache with typical migraine...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT06921109 · University of Liege Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇧🇪 BE

Who might be able to join this trial: - You have been experiencing headaches for at least 6 months, OR you have been diagnosed with migraines and/or chronic tension-type headaches by a children's brain specialist (pediatric neurologist) using recognized medical guidelines. Who may not be able to join: - You have been...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06938178 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇮🇹 IT

Who might be able to join this trial: - Adults who have been diagnosed with high-frequency episodic migraine or chronic migraine, meaning they experience between 8 and 14 migraine days per month, based on recognised international headache diagnostic guidelines. - People whose migraine treatment has been stable and unch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06943625 · Riphah International University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2026
🇵🇰 PK

Who might be able to join this trial: - People diagnosed with episodic migraine or chronic migraine, as defined by the International Headache Society - People whose migraine pain has averaged a score of 5 or higher (out of 10) on a pain scale over the 4 weeks before joining the study Who may not be able to join: - Peo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06953622 · Peking University Third Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇨🇳 CN

Who might be able to join this trial: - You have been diagnosed with migraine according to the standard international guidelines for headache disorders (ICHD-3). - You have been confirmed to have a small hole in the heart called a patent foramen ovale (PFO), detected through a heart ultrasound test. - You are willing t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06959004 · Danish Headache Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2026
🇩🇰 DK

**Who might be able to join this trial:** - People aged 18 to 65 years old at the time of screening - People who weigh between 50 and 100 kg - People who have had a history of migraine without aura for at least 12 months, diagnosed according to established international headache criteria - People who have had an averag...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06961864 · University of Minnesota Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 March 2030
🇺🇸 US

Who might be able to join this trial: **For people with Visual Snow Syndrome (VSS):** - People aged between 18 and 60 years old - People with good vision (20/25 or better in each eye), either naturally or with glasses — MRI-compatible glasses will be provided if needed - People who are able to follow study instruction...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06972056 · Mayo Clinic Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 March 2029
🇺🇸 US

**Who might be able to join this trial:** - You are between 18 and 70 years old at the time of joining the study - You have been diagnosed with migraine with aura, migraine without aura, and/or chronic migraine - Your migraines started before you were 50 years old - You have been experiencing migraines for at least 12...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT06974617 · Cairo University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2025
🇪🇬 EG

Who might be able to join this trial: - You are between 18 and 65 years old. - You can be male or female. - You have chronic migraine, meaning you have headaches on 15 or more days per month for at least 3 months, and at least 8 of those days involve migraine headaches (as defined by international headache guidelines)....

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT06995729 · Pfizer Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 12 August 2027
🇺🇸 US

Who might be able to join this trial: - Children between 6 and 11 years old (up to but not including 12 years). - Children who have a documented medical history of migraines (with or without visual or sensory disturbances before the headache) for at least 6 months before the initial screening appointment. - Children wh...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07015411 · Benfida, a department of Handi-Move Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2025
🇧🇪 BE

**Who might be able to join this trial:** - Adults aged between 18 and 75 years (male or female) - People with a confirmed migraine diagnosis (with or without aura) based on recognised international headache guidelines, meaning they have had at least 5 migraine attacks that last between 4 and 72 hours, with specific f...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07018700 · Merz Therapeutics GmbH Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 1 March 2027
🇦🇹 AT🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL +5 more

**Who might be able to join this trial:** - You have been diagnosed with episodic migraine (with or without aura) for at least 12 months, and you can tell the difference between your migraines and other types of headaches - Your migraines first started before you were 50 years old - In each of the 3 months before your...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07018713 · Merz Therapeutics GmbH Phase 3 · 13 countries Recruiting
Recruiting Phase 3 Est. completion 1 October 2027
🇦🇹 AT🇨🇦 CA🇨🇿 CZ🇩🇰 DK🇫🇷 FR🇩🇪 DE🇮🇹 IT🇵🇱 PL +5 more

Who might be able to join this trial: - People who have been diagnosed with chronic migraine (with or without aura) for at least 12 months, and who can tell the difference between their migraines and other types of headaches - People whose migraines first started before the age of 50 - People who have had at least 15 h...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07021859 · Danish Headache Center Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 June 2026
🇩🇰 DK

Who might be able to join this trial: - People who are between 18 and 65 years old at the time of screening - People who have had a diagnosis of migraine with aura for at least 12 months, based on recognised international headache disorder guidelines - People who have had at least one day per month on average, over the...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07022496 · Ain Shams University Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 July 2025
🇪🇬 EG

**Who might be able to join this trial:** - People who have been diagnosed with migraine (with or without aura, episodic, or chronic) according to standard medical diagnostic guidelines (known as ICHD-3) **Who may not be able to join:** - People with a history of irregular heart rhythms, high blood pressure, reduced b...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07029126 · Fondazione Policlinico Universitario Campus Bio-Medico Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2025
🇮🇹 IT

Who might be able to join this trial: **For patients with migraine:** - Adults (male or female) who have been diagnosed with migraine (with or without aura) or chronic migraine, according to standard medical guidelines - People whose migraine began before the age of 50 - People who have some symptoms of depression, me...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07040813 · Oslo University Hospital Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 January 2029
🇳🇴 NO

**Who might be able to join this trial:** - People aged 18 to 70 years, of any sex, who are willing and able to give signed written consent to participate - People who have been diagnosed with chronic migraine, as defined by the International Classification of Headache Disorders (version 3, criteria 1.3) - People whos...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07061847 · Northwell Health Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 10 March 2027
🇺🇸 US

**Who might be able to join this trial:** - Adults between 18 and 75 years old who have been diagnosed with Chronic Daily Headache that has not responded well to medical treatments. - People whose headaches occur on 15 or more days per month, and have done so for at least 3 months at a time, as defined by internationa...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07071506 · University of Aarhus Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2028
🇩🇰 DK

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have been diagnosed with migraines (with or without "aura," such as visual disturbances before a headache) for at least 1 year, based on recognised medical guidelines - You have chronic migraine, meaning you have headaches on 15 or mo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07072910 · Aarhus University Hospital Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 March 2028
🇩🇰 DK

Who might be able to join this trial: - People who are 18 years of age or older - People who have been diagnosed with episodic migraine according to recognised international diagnostic standards - People who have experienced between 4 and 14 migraine days per month, on average, over the 3 months before joining the tria...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07093138 · Alasht Pharmed Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 16 September 2025
Iran

**Who might be able to join this trial:** - People aged 18 to 55 years, both male and female - People whose migraines first started before the age of 50 - People who have been diagnosed with migraine (according to an international medical standard called ICHD-3) for at least one year - People who have had between 2 and...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07103694 · IRCCS San Raffaele Roma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 December 2026
🇮🇹 IT

Who might be able to join this trial: - People who are 18 years of age or older - Both men and women are eligible - People who are willing to read and sign an informed consent form - People who have episodic migraine and are using medication specifically for migraine attacks - People who have high-frequency episodic mi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07159750 · Hospital Universitari Vall d'Hebron Research Institute Not Applicable · 13 countries Recruiting
Recruiting Not Applicable Est. completion 1 January 2026
🇦🇷 AR🇨🇱 CL🇨🇴 CO🇭🇷 HR🇩🇪 DE🇮🇹 IT🇲🇾 MY🇳🇴 NO +5 more

Who might be able to join this trial: - People who have been diagnosed with migraine according to a recognised international diagnostic standard (called ICHD-III) - People for whom a doctor has prescribed one of the following medicines for migraine: erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant, or rimeg...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07163416 · IRCCS San Raffaele Roma Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 15 December 2025
🇮🇹 IT

**Who might be able to join this trial:** - Adults aged 18 or older, of any sex - People who have a confirmed diagnosis of episodic migraine (headaches on fewer than 15 days per month), with or without aura, or chronic migraine (headaches on 15 or more days per month), with or without headaches caused by overusing pain...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07170176 · First Affiliated Hospital Xi'an Jiaotong University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2027
🇨🇳 CN

Who might be able to join this trial: - Adults between 18 and 60 years old - People who have been diagnosed with a patent foramen ovale (PFO) — a small natural opening in the heart that did not close after birth — with a significant flow of blood passing through it in the wrong direction - For the case group: People wh...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07177885 · University Hospital, Clermont-Ferrand Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2028
🇫🇷 FR

**Who might be able to join this trial:** - Women who were born female and are not yet through menopause, between the ages of 18 and 50 - Men who were born male, between the ages of 18 and 50 - People who have been diagnosed with migraines (based on standard medical guidelines known as ICHD-3) - People who have been id...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07223008 · Johns Hopkins University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2027
🇺🇸 US

Who might be able to join this trial: - People aged between 18 and 80 years old. - People who have been diagnosed with chronic migraine affecting both sides of the head, with their first migraine occurring before age 50, based on recognised international headache diagnostic standards. - People whose chronic migraines h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07233941 · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 May 2027
🇮🇹 IT

Who might be able to join this trial: - People who are willing and able to provide written consent to participate. - People aged between 18 and 65 years old. - People who have been diagnosed with migraine according to an internationally recognised set of headache disorder guidelines (called ICHD-3). - People who have h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07267819 · Uniformed Services University of the Health Sciences Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 6 June 2028
🇺🇸 US

Who might be able to join this trial: - You must be at least 18 years old - You must be able to read and sign a consent form written in English - You must be a US Government employee, or an adult family member of a US Government employee - You must have already received Xeomin injections (a type of botulinum toxin trea...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07268768 · IRCCS Centro Neurolesi Bonino Pulejo Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 November 2028
🇮🇹 IT

Who might be able to join this trial: - People who are between 18 and 60 years old - People who have been diagnosed with chronic or episodic headache - People who are attending a Headache Outpatient Clinic Who may not be able to join: - People who have serious psychiatric or neurological conditions - People who have a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07279623 · Abilion Medical Systems AB Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 September 2026
🇸🇪 SE

**Who might be able to join this trial:** - You are between 18 and 65 years old at the time of screening. - You have been officially diagnosed by a doctor with migraine without aura, migraine with aura, or chronic migraine. - Your migraines first started before you turned 50 years old. - You have had migraines for at l...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07301008 · Medstar Health Research Institute Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 1 September 2026
🇺🇸 US

**Who might be able to join this trial:** - People who have had episodic migraine (with or without aura) for at least 1 year, diagnosed according to standard international headache guidelines - Adults aged 18 or older - People who have had an average of 2 to 8 moderate or severe migraine attacks per month over the las...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07304518 · Sichuan Purity Pharmaceutical Technology Co., Ltd. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 September 2026
🇨🇳 CN

**Who might be able to join this trial:** - People aged 18 to 75 years (inclusive), of any gender - People with a body mass index (a measure of body weight relative to height) below 35 - People who have had migraines (with or without aura) for at least 1 year, diagnosed according to recognised international headache g...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07310290 · AbbVie Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - You have had between 4 and 10 migraine days per month with moderate to severe pain in each of the 3 months before your first study visit (this still applies if you are on preventive migraine treatment that has reduced your migraines into this range). - You are currently prescribe...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07328685 · Mustafa Kemal University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 20 March 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who have been diagnosed with migraine - People who experience at least 3 migraine attacks per month - People between the ages of 18 and 55 who are willing to take part in the study Who may not be able to join: - People who have a history of headaches caused by another und...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07347028 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with knee osteoarthritis, confirmed by X-ray evidence and assessed by at least two qualified doctors, with a physical examination also finding at least one tender muscle knot (trigger point) in the area. - People whose knee osteoarthritis symptoms h...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07347041 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with hip osteoarthritis, confirmed by X-ray imaging and reviewed by at least two doctors, and a physical examination has found at least one tender muscle knot (trigger point) in the area. - Your hip pain or condition has been present for more than 3 m...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07347054 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with shoulder osteoarthritis, confirmed by X-ray evidence and agreed upon by at least two doctors, and a physical examination has found at least one tender "knot" or tight spot in your shoulder muscle. - Your shoulder pain or condition has been present...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07347067 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

Who might be able to join this trial: - People who have been diagnosed with migraine by at least two pain specialists or neurologists - People whose migraines have been ongoing for at least 3 months - People aged between 18 and 65 years - People whose pain is still rated at 3 or higher out of 10 on a pain scale, even a...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07347730 · Beijing Tiantan Hospital Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2026
🇨🇳 CN

**Who might be able to join this trial:** - You have been diagnosed with cervicogenic headache (a type of headache that comes from the neck) by at least two pain specialists or neurologists - Your headaches have been going on for at least 3 months - You are between 18 and 65 years old - Your pain level is still 3 or hi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07348783 · Karolinska Institutet Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 December 2027
🇸🇪 SE

**Who might be able to join this trial:** - You have been diagnosed with chronic migraine and/or cluster headache (also called Horton's headache) - You are between 18 and 65 years old - You experience 15 or more headache days per month, with at least 8 of those days being migraine days - You have been diagnosed with ch...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07349004 · Azienda Usl di Bologna Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 24 November 2025
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with migraine with aura, as defined by an international medical classification system for headache disorders - People who are 18 years of age or older - People of any sex - People who have given written consent to take part in the study Who may not...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07354126 · Muhammad Aamir Latif Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 28 February 2026
🇵🇰 PK

Who might be able to join this trial: - Children of any gender - Children aged between 8 and 15 years old - Children who have been diagnosed with migraine (with or without visual or sensory warning signs before the headache) according to recognised international diagnostic guidelines - Children who have had at least 4...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07402954 · The University of Texas Medical Branch, Galveston Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 August 2027
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older - People who have chronic migraine, a prolonged severe migraine episode (status migrainosus), or facial/head pain that has not responded to the strongest available standard treatments, and who are already scheduled to receive a lidocaine infusion into a sp...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07419607 · Medical University Innsbruck Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2026
🇦🇹 AT

**Who might be able to join this trial:** - You have been diagnosed with migraine according to a recognised medical classification system called ICHD-3 - You are between 13 and 17 years old - You live within 35 kilometres of the trial location, or you travel close to the trial location every day for school or work even...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07454798 · Children's Mercy Hospital Kansas City Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 May 2028
🇺🇸 US

**Who might be able to join this trial:** - You are between 10 and 16 years old (inclusive) - You have been diagnosed with migraine (with or without aura, or chronic migraine) by a headache specialist - You get at least 4 migraine headaches per month - You have periods between migraines where you are headache-free **W...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07476053 · Arizona State University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇺🇸 US

Who might be able to join this trial: - People who have been diagnosed with migraine (with or without aura or light sensitivity) according to the standard international headache diagnosis guidelines. - People who experience more than 4 headache days per month and at least 3 migraine attacks per month. - People who repo...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07496034 · Tsai, Chueh-Yi, MD Phase 3 · 1 country Recruiting
Recruiting Phase 3 Est. completion 31 December 2026
🇹🇼 TW

**Who might be able to join this trial:** - You are between 18 and 70 years old. - You have had migraines on and off (not constant) for at least 12 months before the screening period, diagnosed according to standard medical guidelines or by a doctor. - During the 28-day screening period, you experienced headaches on a...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07500558 · Minia University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 22 March 2027
🇪🇬 EG

**Who might be able to join this trial:** - People who have been diagnosed with chronic migraine, meaning they experience 15 or more headache days per month for more than 3 months, with at least 8 of those days being migraine days, confirmed by keeping a headache diary for 4 weeks before the study starts. - People for...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07518069 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 9 April 2027
🇮🇹 IT

Who might be able to join this trial: - You have been diagnosed with Menière's Disease that meets the official diagnostic standards set by the Barany Society (an international medical organisation that defines criteria for inner ear conditions) Who may not be able to join: - You have already had surgery related to you...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07554664 · Bozok University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 10 May 2026
Turkey (Türkiye)

Who might be able to join this trial: - You are between 18 and 65 years old - You have worked in an office job for at least 6 months - You spend at least 4 hours a day working at a desk - You are able to read and understand Turkish - You are willing to take part voluntarily - If you have been diagnosed with migraines,...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07567300 · Bozok University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 17 June 2026
Turkey (Türkiye)

Who might be able to join this trial: - People who are between 18 and 65 years old - People who are able to read and understand Turkish - People who agree to take part voluntarily - People who have been diagnosed with episodic or chronic migraine, based on the International Classification of Headache Disorders (3rd edi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07571889 · Association of Migraine Disorders Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 January 2027
🇺🇸 US

**Who might be able to join this trial:** - You are 18 years old or older - You are any gender - You are able to understand and agree to take part in the study by signing a consent form - You meet the medical requirements for a specific migraine treatment (onabotulinumtoxinA), meaning you have at least 2 days per month...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07573488 · Susanne Wegener Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 April 2027
🇨🇭 CH

**Who might be able to join this trial:** - You are between 18 and 65 years old - You have been diagnosed with episodic migraine (a type of migraine that comes and goes) by a headache specialist, following recognised diagnostic guidelines - You have had between 4 and 14 headache days per month on average over the past...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07579481 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 May 2026
🇮🇹 IT

**Who might be able to join this trial:** - You are over 18 years old - You have been diagnosed with depression (based on DSM-5 guidelines) and have recently started taking Vortioxetine (for no more than one week) - You have depression and may also have symptoms of anxiety - Your depression is rated as moderate to sev...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07594769 · Pfizer Phase 1 · 1 country Recruiting
Recruiting Phase 1 Est. completion 31 August 2026
🇧🇪 BE

**Who might be able to join this trial:** - Adults aged 18 or older (or the minimum age required by local rules) who are considered generally healthy based on medical history, physical examination, blood tests, and heart trace (ECG) results. - People with a body mass index (BMI) between 16 and 32, and a body weight abo...

Phase 1: ~10% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07609914 · Pfizer Phase 4 · 1 country Recruiting
Recruiting Phase 4 Est. completion 15 May 2028
🇺🇸 US

Who might be able to join this trial: - Adults aged 18 or older who have had migraines (with or without aura) for at least 1 year, diagnosed according to standard international headache guidelines - People who are currently using an approved acute migraine treatment, and who have had an average of 6 to 14 migraine days...

Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.
NCT07616128 · Evommune, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 October 2027
🇺🇸 US

Who might be able to join this trial: - People who are aged 18 to under 65 years old - People who have been diagnosed with migraine, with or without aura, according to standard international diagnostic guidelines - People who have tried migraine prevention treatments in the past that did not work for them - People who...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07617441 · Istituto per la Ricerca e l'Innovazione Biomedica Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2028
🇮🇹 IT

**Who might be able to join this trial:** *For people with chronic migraine:* - Adults between 18 and 75 years of age - People who have been diagnosed with non-responsive chronic migraine (a form of migraine that does not improve with standard treatments) according to established medical guidelines - People who experi...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07626307 · Istituto Auxologico Italiano Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2027
🇮🇹 IT

**Who might be able to join this trial:** - People aged between 18 and 70 years old (inclusive) - People who have been diagnosed with migraine by a neurologist who specialises in headache conditions - People whose headache impact score (measured by a tool called the HIT-6) is 42 or higher, indicating significant impact...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07642414 · Hinge Health, Inc Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 October 2026
🇺🇸 US

**Who might be able to join this trial:** - People who are 18 years of age or older - People who have a documented or clinically recognised history of episodic or chronic migraine (with or without aura) for at least 12 months, confirmed through medical records, pharmacy prescription history, or a validated screening t...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07645924 · Kallyope Inc. Phase 3 · 2 countries Recruiting
Recruiting Phase 3 Est. completion 1 February 2027
Puerto Rico🇺🇸 US

**Who might be able to join this trial:** - People aged 18 to 75 years old at the time of signing the consent form, of any gender. - People who have had migraines (with or without aura) for more than one year, where untreated migraines typically last between 4 and 72 hours. - People who have had at least 2 but no more...

Phase 3: ~65% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07646613 · Aspeya, Inc. Phase 2 · 1 country Recruiting
Recruiting Phase 2 Est. completion 1 December 2026
🇺🇸 US

Who might be able to join this trial: - People who are able to understand what the study involves and are willing to sign a written consent form - People aged 18 to 65 years old at the time of screening - People with a Body Mass Index (BMI) between 18.5 and 35 at the time of screening - People who have a documented his...

Phase 2: ~30% of drugs entering this phase reach regulatory approval (industry-wide historical average, not specific to this trial)
NCT07656922 · Ankara Yildirim Beyazıt University Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 July 2026
Turkey (Türkiye)

**Who might be able to join this trial:** - You are between 18 and 55 years old - You have been diagnosed with migraine by a neurologist using recognised international diagnostic guidelines - You have at least 3 migraine attacks per month - You are willing to take part and sign a consent form agreeing to participate *...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07671703 · Hochschule Osnabruck Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 31 December 2027
🇩🇪 DE

Who might be able to join this trial: - People who are between 18 and 70 years old. - People who have been diagnosed with migraine by a headache specialist, using a recognised international standard for diagnosing headache disorders (ICHD-3). - People who have had migraine symptoms for more than 3 months, with headache...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07681466 · University of Roma La Sapienza Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 March 2027
🇮🇹 IT

Who might be able to join this trial: - People who have been diagnosed with episodic migraine, chronic migraine, or chronic migraine with medication overuse headache, based on recognised international diagnostic guidelines - People between 18 and 65 years of age - People who had at least 2 migraine days in the month be...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07694063 · University of Seville Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 30 October 2026
🇪🇸 ES

Who might be able to join this trial: - Adults between 18 and 65 years old - People who have been diagnosed with episodic high-frequency migraine, based on recognised international diagnostic guidelines - People whose migraine diagnosis has been confirmed by a neurologist - People who have had migraines for at least on...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
NCT07720765 · IRCCS San Raffaele Not Applicable · 1 country Recruiting
Recruiting Not Applicable Est. completion 1 April 2030
🇮🇹 IT

Who might be able to join this trial: **For people with a neurological condition:** - People who have been diagnosed with a central nervous system condition, such as Multiple Sclerosis, Alzheimer's disease, Parkinson's disease, migraine, or a similar headache disorder - People who are older than 18 years of age - Peop...

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Advocacy and support in Australia

Organisations that can offer information, support, or connection for Migraine. Where more than one is listed, they serve different needs or regions, so choose whichever fits your situation.

A few organisations support people with migraine: Migraine and Headache Australia (part of the Brain Foundation), Migraine Australia, and the Migraine Foundation Australia. It's worth checking which one lines up best with what you're after.

This is a starting point, not medical advice or an endorsement. Contact details change; search the organisation name to find its current website.